Omega Advisors’s Editas Medicine EDIT Stock Holding History

Omega Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-50,000	Closed	-$1.12M	–	85
2017 Q1	$1.12M	Buy	+50,000	New	+$1.04M	0.04%	74

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

PVMCV

Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Omega Advisors's EDIT Position: Q2 2017 in Review

Omega Advisors sold out of Editas Medicine (EDIT) in Q2 2017, closing a stake of 50,000 shares — an estimated $1.12M sold.

Omega Advisors first reported a position in EDIT in Q1 2017 and held it in 1 quarter. The position peaked at $1.12M in Q1 2017. 110 funds tracked by Wall St. Rank hold EDIT as of Q2 2017.

Omega Advisors reported no remaining Editas Medicine position as of Q2 2017 after selling out during the quarter.
Omega Advisors sold 50,000 Editas Medicine shares in Q2 2017, an estimated $1.12M.
Omega Advisors first reported a position in Editas Medicine in Q1 2017 and held it in 1 quarter.
Omega Advisors's Editas Medicine position peaked at $1.12M in Q1 2017.
110 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2017.

Based on Omega Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.